|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7780038||TEVA BRANDED PHARM||Dispensing apparatus with dosage counter|| |
(3 years from now)
|US10188811||TEVA BRANDED PHARM||Nasal spray device|| |
(8 years from now)
Qnasl is owned by Teva Branded Pharm.
Qnasl contains Beclomethasone Dipropionate.
Qnasl has a total of 2 drug patents out of which 0 drug patents have expired.
Qnasl was authorised for market use on 23 March, 2012.
Qnasl is available in aerosol, metered;nasal dosage forms.
The generics of Qnasl are possible to be released after 21 October, 2031.
Market Authorisation Date: 23 March, 2012
Dosage: AEROSOL, METERED;NASAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic